Progressive Myoclonic Epilepsy in Dravet Syndrome When Stiripentol-Based Therapy Has Not Achieved Adequate Seizure Reduction

This protocol applies to patients with progressive myoclonic epilepsy in the context of Dravet syndrome whose convulsive seizures have not been sufficiently controlled on a first-line regimen, and for whom a structured next-line approach is needed.

Clinical Context — Dravet Syndrome

Dravet syndrome is an early childhood-onset epilepsy syndrome characterized by drug-resistant seizures, frequent episodes of status epilepticus, and the development of neurocognitive impairment. Progressive myoclonic epilepsy in this setting carries a high burden of treatment-refractory convulsions.

Previous Treatment — Insufficient Response

When stiripentol administered in conjunction with clobazam and valproate has not achieved adequate reduction in convulsive seizures, escalation to a next-line protocol is indicated. This page describes the structured approach taken after that failure condition.

Next-Line Approach (partial overview)

In this situation, the next step may involve a pharmacological agent such as fenfluramine, among further options specified in the full protocol. The complete regimen, selection criteria, and sequencing remain in the structured evidence-based protocol below.

Clinical goal: ≥50% reduction in convulsive seizure frequency

Instant Access to Structured Evidence-Based Regimens

References

Dravet syndrome is an early childhood-onset epilepsy syndrome characterized by drug-resistant seizures, frequent episodes of status epilepticus, and the development of neurocognitive impairment.

Fenfluramine demonstrated significant improvements in monthly convulsive seizure frequency in patients with Dravet syndrome whose conditions were insufficiently controlled with stiripentol-inclusive antiepileptic drug regimens.

The percentage of patients with at least a 50% reduction in convulsive seizure frequency was 43% with cannabidiol and 27% with placebo.

View source ↗